Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis

By Mesa Ruben A   Tefferi Ayalew  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 3, 2009-09 ,pp. : 471-479

Informa Healthcare

Access to resources Recommend Favorite

Polycythemia vera: can we do better?

By Shariff Farah   Harrison Claire  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 687-689

Informa Healthcare

Access to resources Recommend Favorite

Enhanced Expression of the Local Haematopoietic Bone Marrow Renin–Angiotensin System in Polycythemia Rubra Vera

By Aksu S   Beyazit Y   Haznedaroglu IC   Kekilli M   Canpinar H   MisirliogĞlu M   Uner A   Tuncer S   Sayinalp N   Büyükaşik Y   Goker H   Ozcebe OI  

The Journal of International Medical Research, Vol. 33, Iss. 6, 2005-11 ,pp. : 661-667

Field House Publishing

Access to resources Recommend Favorite

Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 355-356

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging drugs for focal epilepsy

By Mula Marco  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 1, 2013-03 ,pp. : 87-95

Informa Healthcare

Access to resources Recommend Favorite